文献速递肝病

改良肝性脑病分期工具的研发与临床评估

Development and Clinical Evaluation of the Modified Hepatic Encephalopathy Staging Tool.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-09-18

本研究开发了改良肝性脑病分期工具(mHEST),旨在替代 observer 间差异较大的 West Haven 标准。第一部分由 6 国 49 名专业人员评估视频案例,观察者间一致性达 83.3%-100%。第二部分纳入 128 例失代偿期肝硬化住院患者,mHEST 的观察者间信度(κ=0.934)显著优于 West Haven(κ=0.367),且 mHEST 分级与 1 年死亡率相关,低分级(0-1)独立预测 1 年生存改善。

要点

  • mHEST 观察者间信度 κ=0.934,显著高于 West Haven 的 κ=0.367。
  • mHEST 分级与血氨水平呈阶梯式升高相关,而 West Haven 无此关联。
  • 低 mHEST 分级(0-1)独立预测失代偿期肝硬化患者 1 年生存改善。

核心结论

  • mHEST 是一种用户友好、可靠且预后准确的肝性脑病评估工具,性能优于 West Haven 标准。
  • mHEST 已被美国食品药品监督管理局接受作为临床试验终点。

研究设计与样本

  • 第一部分:6 个国家 49 名医护人员观看 6 个展示不同肝性脑病分期的视频案例,经 mHEST 培训后间隔 5-10 天两次评估,分析观察者间和观察者内一致性。
  • 第二部分:前瞻性单中心研究纳入 128 例失代偿期肝硬化住院患者,培训后的专业人员独立使用 West Haven 标准和 mHEST 评估肝性脑病,比较诊断一致性、预后性能及对已有评分系统的影响。

主要发现

  • 第一部分观察者间一致性范围为 83.3% 至 100%,观察者内一致性范围为 81.0% 至 100%。
  • 第二部分 mHEST 的观察者间信度 κ=0.934,显著高于 West Haven 的 κ=0.367。
  • mHEST 改善了包含肝性脑病的评分系统性能,包括 Child-Pugh 和 CLIF-C 器官衰竭评分。
  • 血浆氨水平随 mHEST 分级升高呈阶梯式增加,但与 West Haven 分级无此关联。
  • mHEST 分级与 1 年死亡率相关,低 mHEST 分级(0-1)独立预测 1 年生存改善。

关键数值与推荐

  • 观察者间信度:mHEST κ=0.934,West Haven κ=0.367。
  • 第一部分观察者间一致性 83.3%-100%,观察者内一致性 81.0%-100%。
  • 低 mHEST 分级(0-1)独立预测 1 年生存改善。

临床怎么用

  • 在失代偿期肝硬化住院患者中,可采用 mHEST 替代 West Haven 标准进行肝性脑病分期评估,以提高观察者间一致性。
  • mHEST 分级可用于预后判断,低分级(0-1)提示 1 年生存改善。
  • mHEST 已被 FDA 接受为临床试验终点,适用于规范化临床试验中的肝性脑病评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatic encephalopathy (HE) is a serious complication of advanced cirrhosis, requiring accurate and consistent diagnosis and staging. The commonly used West Haven criteria have substantial interobserver variability. This study aimed to develop the modified Hepatic Encephalopathy Staging Tool (mHEST) as a more objective and reproducible HE assessment method for regulated clinical trials. METHODS: This study consisted of 2 parts. In part 1, 49 health care professionals from 6 countries evaluated 6 video vignettes depicting different HE stages. After viewing a mHEST training video, participants assessed the vignettes twice (5-10 days apart). Inter- and intrarater agreement were analyzed. In Part 2, a prospective single-center study enrolled 128 hospitalized patients with decompensated cirrhosis. Trained professionals independently assessed HE using both West Haven criteria and mHEST. Diagnostic consistency, prognostic performance, and impact on established scoring systems were compared. RESULTS: In part 1, inter-rater concordance ranged from 83.3% to 100%, and intrarater agreement from 81.0% to 100%. In part 2, inter-rater reliability was significantly higher for mHEST than West Haven (κ = 0.934 vs 0.367). mHEST improved the performance of HE-containing scores, including Child-Pugh and CLIF-C Organ Failure. Plasma ammonia levels increased stepwise with mHEST grades, but not with West Haven. mHEST grades correlated with 1-year mortality, and low mHEST grades (0-1) independently predicted improved 1-year survival. CONCLUSIONS: MHEST is a user-friendly, reliable, and prognostically accurate HE assessment tool that outperforms West Haven criteria and has been accepted by the United States Food and Drug Administration as a clinical trial endpoint.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kerbert AJC, Chesta C, Balachandran P, et al. Development and Clinical Evaluation of the Modified Hepatic Encephalopathy Staging Tool. Clin Gastroenterol Hepatol. 2026. PMID: 42759682. doi:10.1016/j.cgh.2026.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。